Aspirin for the Primary Prevention of Cardiovascular Events: An Update of the Evidence for the U.S. Preventive Services Task Force
about
Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trialsAspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American CoReview of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?Causal relationship of susceptibility genes to ischemic stroke: comparison to ischemic heart disease and biochemical determinantsAspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes.Standards of medical care in diabetes--2010.Squatting and risk of colorectal cancer:a case-control studyInfluence of sex hormones and phytoestrogens on heart disease in men and womenAspirin for primary cardiovascular prevention: when is it worth the risks?Thrombotic events associated to aspirin therapy.Applied Healthspan engineering.Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status.Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians.Antiplatelet combinations for prevention of atherothrombotic eventsGenome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Delineating the Hemostaseome as an aid to individualize the analysis of the hereditary basis of thrombotic and bleeding disorders.Cardiovascular disease in HIV patients: from bench to bedside and backwards.Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study.Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy womenDrugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews.Aspirin might reduce the incidence of pancreatic cancer: A meta-analysis of observational studies.Family practice patients' use of acetylsalicylic acid for cardiovascular disease prevention.Association between use of specialty dietary supplements and C-reactive protein concentrations.Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis.Antiplatelet therapy for every diabetic person?Low-dose bisphenol A and estrogen increase ventricular arrhythmias following ischemia-reperfusion in female rat hearts.The use of daily aspirin, nutritional supplements and alternative medications among Amish and non-Amish living in Ohio Appalachia.Cost-Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease.Associations between aspirin and other non-steroidal anti-inflammatory drugs and aortic valve or coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study.Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: a cohort study in primary care.The decline effect in cardiovascular medicine: is the effect of cardiovascular medicine and stent on cardiovascular events decline over the years?The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors.Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approachHigher rate of microscopic hematuria in elderly patients who take regular doses of aspirin: Result from AHAP Study.Low-dose aspirin use and recurrent gout attacks.Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.Use of evidence-based therapy for the prevention of cardiovascular events among older people.Antiplatelet drug interactions.
P2860
Q21132402-2EB6E33A-0654-4E14-944B-EA1A01EE80B2Q22241289-2D54029D-BD72-4A8C-882D-6D1080B070C1Q22241777-9C7EA8A4-751B-4A4C-A5B2-70024FCA8391Q28472816-62FEEC0F-3CF0-4C44-813B-E754D68CA5CCQ33501445-DC3FB07B-F842-4AFB-A0DB-3E2A983B3F8AQ33554238-47388290-D172-443C-9777-BAE829C6EEB5Q33597382-8D547870-76A3-432F-8B86-81AB69F70430Q33721061-8A9C0083-383C-4C92-9003-14739207638AQ33774734-48FD25ED-C682-4B5B-B617-56C6D43ABF04Q34111104-F9580963-4D40-4136-92B0-B2E7E8ECCCE5Q34157133-2458C60E-B27B-424E-9F7A-D4EB0A6C485DQ34433987-598EE64A-A9D2-4A05-9A52-FD7461279BF6Q34459060-49469604-0C22-4378-BD11-7D8C96E0016FQ34566264-AC22842C-0DF3-4905-AB4A-6D3A945031BBQ34674600-FE35806B-B2EC-4175-AAE1-F361233857EFQ34736194-1D8AFCA5-9EB6-4507-B2B1-9B290C64CD43Q35105533-CDD5206C-F3E5-4B9B-8000-EC17BA35E89DQ35203971-61F49334-207F-4668-942A-EFE6B48A7926Q35529084-58CA0C11-7F6B-4221-8F35-2BE2720608ACQ35953560-377D9C23-3848-48E7-927C-B2748E0AF32AQ36082805-AABEF5F5-6AEE-4D5D-A82A-A28B279C2CC2Q36187239-0A285A35-5924-43C9-8C2F-4842B6DF0097Q36564342-8284F08C-B936-4819-8880-2D38F0441631Q36606633-AA0BC726-E720-48B2-A43C-1674ABCFB2CDQ36668917-32C087EE-10B1-4CCB-8430-44BD7C08F675Q36783726-BD349289-8DD2-4F6A-8A0E-CA9252EBF598Q36799534-F2FB03E5-C962-4B6E-B5E1-300CAE00708BQ36834150-D5FCE618-3890-4A3E-A743-69A8AC0C49D0Q36836401-7DF41585-8ADB-4B8B-9FD2-6CE6764991A9Q37047130-471F7E27-B371-4E73-B967-8539BFB73EE7Q37065028-E8D93283-0BE4-457D-9F25-E9B63E3B3755Q37098181-4F92406E-CB2D-4025-B13B-6584E87C7C5CQ37194881-CA660224-A13F-4D62-9E65-15FB0BC34A13Q37285574-57E757EC-8F33-451C-B322-EE0BD9EA4D44Q37497192-C1FC74DD-8587-49E5-868B-DB8D52305E62Q37517681-2B44622F-03AB-4ADF-B8A1-D95F28775C1BQ37536810-C0376A7B-F713-4C5D-ADF7-E4318419D65CQ37588694-C7F9844C-AA0E-4F5E-B74F-C4814D1EAF63Q37783853-244FA94D-378C-45FA-AB41-8483B116653EQ37809111-C9B455E0-B7A9-423E-8F59-DB46C13762DF
P2860
Aspirin for the Primary Prevention of Cardiovascular Events: An Update of the Evidence for the U.S. Preventive Services Task Force
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Aspirin for the Primary Preven ...... Preventive Services Task Force
@ast
Aspirin for the Primary Preven ...... Preventive Services Task Force
@en
Aspirin for the Primary Preven ...... Preventive Services Task Force
@en-gb
type
label
Aspirin for the Primary Preven ...... Preventive Services Task Force
@ast
Aspirin for the Primary Preven ...... Preventive Services Task Force
@en
Aspirin for the Primary Preven ...... Preventive Services Task Force
@en-gb
prefLabel
Aspirin for the Primary Preven ...... Preventive Services Task Force
@ast
Aspirin for the Primary Preven ...... Preventive Services Task Force
@en
Aspirin for the Primary Preven ...... Preventive Services Task Force
@en-gb
P2093
P1476
Aspirin for the Primary Preven ...... Preventive Services Task Force
@en
P2093
Stephen Ko
Therese Miller
Tracy Wolff
P304
P356
10.7326/0003-4819-150-6-200903170-00009
P407
P577
2009-03-01T00:00:00Z